Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Enbrel Facility On Track For Third Quarter '02; CHF Research Dropped

Executive Summary

Wyeth-Ayerst expects to begin producing additional Enbrel (etanercept) supply in the third quarter of 2002 out of its West Greenwich, R.I. manufacturing facility, American Home Products CEO Robert Essner said at a May 16 analysts meeting in New York City.
Advertisement

Related Content

Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments
Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments
Wyeth Zosyn Inventory Allocation Program Likely To Last Through 2002
Wyeth Zosyn Inventory Allocation Program Likely To Last Through 2002
Wyeth Low-Dose PremPro Osteoporosis sNDA Filing Planned For June
Wyeth Low-Dose PremPro Osteoporosis sNDA Filing Planned For June
Immunex Decision On Continuing Enbrel CHF Program Awaits Data Analysis
Immunex Decision On Continuing Enbrel CHF Program Awaits Data Analysis
Immunex Enbrel Patient Starts After Jan. 1 Will Be Via Waiting List
Wyeth Will Lose 18.5% Of Marietta Sales If Firm Does Not Comply With GMPs
Advertisement
UsernamePublicRestriction

Register

PS037887

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel